All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Incyte Research Institute presented the discovery of a cyclin-dependent kinase 2 (CDK2) inhibitor, INCB-123667, being developed for the treatment of cyclin E dysregulated cancers.
